A Full-Service Cell Line Development
Rely on Our CLD Experts to Generate Your High-Performing Cell Lines
As the worldwide demand for protein therapeutics has grown, so has the need for suitable production cell lines. Sartorius can help meet this need with our industry-leading cell line development services aimed at the commercial manufacturing of biopharmaceuticals. Based on our unique cell line development technology, we reliably generate high-performing, stable CHO production cell lines on accelerated timelines.
Proprietary and superior CHO cell line development technology that ensures a robust and scalable bioprocess with high product yield (up to 10g/L for monoclonal antibodies) and quality.
From DNA to Research Cell Bank (RCB) in only 9 weeks. No need for time-consuming media and process optimization or scalability studies. Regulatory ready documentation package.
More than 300 cell line development projects. Benefit from our know-how and experience and get your cell line right the first time.
No hidden fees, no cancelation fees, no milestone payments.
Explore Sartorius' Next-Generation Cell Line Development Service
Continuously improving to better meet your needs, we have launched our new CLD Service as part of the 4Cell® CHO platform. CLD Service is powered by the new clone selection technology, CellCelector™ system, to facilitate high-throughput isolation and cloning of individual cells, allowing us to reduce the transition of DNA to RCB significantly down to 9 weeks.
Combined with an efficient expression vector and proprietary CHO host cell line, selected high-producer clones can achieve titers up to 10 g/L with the high-performing 4Cell® SmartCHO media. Additional services for process intensification and genetic engineering have also been added to our service offering.
Track Record
4Cell® CHO Platform Cell Line Development
- Established track record with more than 240 CLD projects
- Our CLD platform works with non-mAbs and “difficult to express” molecules
Single Cell Cloning
Replacing FACS by Sartorius CellCelector™ for Single Cell Cloning
- Speed: removal of pool phase leads to 5 weeks time saving
- Efficiency: improved cell outgrowth leads to minimum loss of high producers due to cell death after single cell cloning
- Regulatory compliance: statistically evaluated procedure granting monoclonality proof for regulatory agencies
Clone Selection
Optimized Clone Selection by Fluorescence-based Productivity Assay and Small-Scale Fed-Batch
- Early elimination of low producers
- Improved detection of high producers
- Proven scalability from clone selection to large-scale biorecators
Additional Services
Genetic Engineering
- FUT8 knock-out option for increased ADCC: service implemented and ready-to-use
- Customized knock-outs possible, e.g. for modified glycosylation profile
Process Intensification
- High-inoculation fed-batch: Achieve higher titer (to standard fed-batch) in comparable time or comparable titer in shorter time
- Selection of high performing perfusion-ready clones in our Ambr15® perfusion mimic
